Eosinophilic Granulomatous Polyangiitis Emerging After Omalizumab Administration: An Asthma Patient Without Systemic Corticosteroids Develops Mononeuritis Multiplex After 22 Days. [PDF]
Wang Z, Lin S, Yang J, Cheng M, Cai M.
europepmc +1 more source
Cytokine imbalance and immune network endotypes underlying heterogeneous response to omalizumab in chronic spontaneous urticaria. [PDF]
Ye YM +5 more
europepmc +1 more source
Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria.
Chen A +8 more
europepmc +1 more source
Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review. [PDF]
Alzayed A.
europepmc +1 more source
Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. [PDF]
Lyu W +9 more
europepmc +1 more source
Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials. [PDF]
Yang Y, Fang C, Jiang Z, Su X, Fan W.
europepmc +1 more source
Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria. [PDF]
Mosnaim G +4 more
europepmc +1 more source
Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines. [PDF]
Ye YM.
europepmc +1 more source
Omalizumab in the management of bullous pemphigoid: a six-month retrospective study. [PDF]
Ürün M, Yılmaz ÇE, Ürün YG.
europepmc +1 more source
Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study. [PDF]
Zheng W +4 more
europepmc +1 more source

